| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5697525 | Cancer Treatment and Research Communications | 2017 | 6 Pages |
Abstract
Our prospective multicenter study suggests that the novel biomarker iXip may be used with a 20% cut-off value in order to reduce the proportion of prostate biopsies by approximately 5%, without missing a single case of cancer. Moreover, higher iXip values are significantly correlated with tumor aggressiveness.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Andrea Gallotta, Gianluca Giannarini, Lucio Laurini, Danilo Zani, Antonio Garbeglio, Stefano Guazzieri, Mario Plebani, Giorgio Fassina, Filiberto Zattoni,